BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 7916907)

  • 21. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis.
    Forastiero RR; Martinuzzo ME; Kordich LC; Carreras LO
    Thromb Haemost; 1996 May; 75(5):717-20. PubMed ID: 8725711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro.
    Di Simone N; Raschi E; Testoni C; Castellani R; D'Asta M; Shi T; Krilis SA; Caruso A; Meroni PL
    Ann Rheum Dis; 2005 Mar; 64(3):462-7. PubMed ID: 15256379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome.
    McNally T; Mackie IJ; Machin SJ; Isenberg DA
    Br J Rheumatol; 1995 Nov; 34(11):1031-6. PubMed ID: 8542203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phospholipid-independent binding of beta 2glycoprotein I by IgA from patients with antiphospholipid syndrome.
    Galazka MW; Keil LB; Kohles J; Petersheim M; DeBari VA
    Ann Clin Lab Sci; 1998; 28(3):153-9. PubMed ID: 9646856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specificities and characteristics of beta 2 glycoprotein I-induced antiphospholipid antibodies.
    Gharavi AE; Sammaritano LR; Bovastro JL; Wilson WA
    J Lab Clin Med; 1995 Jun; 125(6):775-8. PubMed ID: 7769372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'.
    Lutters BC; Derksen RH; Tekelenburg WL; Lenting PJ; Arnout J; de Groot PG
    J Biol Chem; 2003 Sep; 278(36):33831-8. PubMed ID: 12807892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiphospholipid antibodies and platelets.
    De Jong A; Ziboh V; Robbins D
    Curr Rheumatol Rep; 2000 Jun; 2(3):238-45. PubMed ID: 11123065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner.
    Price BE; Rauch J; Shia MA; Walsh MT; Lieberthal W; Gilligan HM; O'Laughlin T; Koh JS; Levine JS
    J Immunol; 1996 Sep; 157(5):2201-8. PubMed ID: 8757347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants.
    Shi W; Chong BH; Chesterman CN
    Blood; 1993 Mar; 81(5):1255-62. PubMed ID: 8443387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome.
    La Rosa L; Meroni PL; Tincani A; Balestrieri G; Faden D; Lojacono A; Morassi L; Brocchi E; Del Papa N; Gharavi A
    J Rheumatol; 1994 Sep; 21(9):1684-93. PubMed ID: 7799350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin.
    Vega-Ostertag M; Harris EN; Pierangeli SS
    Arthritis Rheum; 2004 Sep; 50(9):2911-9. PubMed ID: 15457460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles.
    Galli M; Bevers EM; Comfurius P; Barbui T; Zwaal RF
    Br J Haematol; 1993 Mar; 83(3):466-72. PubMed ID: 8485053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Affinity purified human antiphospholipid antibodies bind normal term placenta.
    Donohoe S; Kingdom JC; Mackie IJ
    Lupus; 1999; 8(7):525-31. PubMed ID: 10483030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes.
    Willems GM; Janssen MP; Pelsers MM; Comfurius P; Galli M; Zwaal RF; Bevers EM
    Biochemistry; 1996 Oct; 35(43):13833-42. PubMed ID: 8901526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis.
    Vlachoyiannopoulos PG; Petrovas C; Tektonidou M; Krilis S; Moutsopoulos HM
    J Clin Immunol; 1998 Nov; 18(6):380-91. PubMed ID: 9857282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
    McNeil HP; Simpson RJ; Chesterman CN; Krilis SA
    Proc Natl Acad Sci U S A; 1990 Jun; 87(11):4120-4. PubMed ID: 2349221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-beta 2 glycoprotein I antibodies. Relationship with antiphospholipid antibodies and thrombosis].
    Ordi Ros J; Falgà Tirado C; Monegal Ferran F; Selva O'Callaghan A; Pérez Pemán P; Cucurull E; Vilardell Tarres M
    Med Clin (Barc); 1995 Feb; 104(7):245-8. PubMed ID: 7731286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of antiphospholipid antibodies on beta(2) glycoprotein I-phospholipid Interaction.
    Gharavi AE; Cucurull E; Tang H; Silver RM; Branch DW
    Am J Reprod Immunol; 1998 May; 39(5):310-5. PubMed ID: 9602248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution.
    Navarro M; Cervera R; Teixidó M; Reverter JC; Font J; López-Soto A; Monteagudo J; Escolar G; Ingelmo M
    Br J Rheumatol; 1996 Jun; 35(6):523-8. PubMed ID: 8670571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.